Singapore MASLD Symposium 2024 Scientific Programme

July 2024

25

Advancing Care in MASLD Programme Time (SGT)
Chairs: Dr. Mark Muthiah & Prof. Hirokazu Takahashi
Welcome Address
Prof. Arun Sanyal, USAView Bio, Dr. Mark Muthiah, SingaporeView Bio
Is MASLD in lean patients the same disease as in overweight and obese individuals? A clinical viewpoint
Prof. Vincent Wong, Hong Kong View Bio
Is MASLD in lean patients the same disease as in overweight and obese individuals? A pathobiological viewpoint
Prof. Sven Francque, Belgium View Bio
Similarities and differences between MetALD and MASLD
Prof. Ajay Duseja,  India View Bio
Specific aetiology SLD in the Asian context
Dr. Daniel Huang Qingyao, Singapore View Bio
Combined Q&A
Tea Break
Chairs: Dr. Daniel Huang & Prof. Ming-Hua Zheng
Interpreting NIT data: Lessons from NIMBLE and LITMUS
Prof. Arun Sanyal, USA View Bio
Intelligent use of NIT’s in clinical practice – moving forward and back from primary care
Prof. Chan Wah Kheong, Malaysia View Bio
A patient centric view of risk assessment: balancing competing risks
Dr. Mark Muthiah, Singapore View Bio
Artificial Intelligence in Liver Histology: Driving Development of MASLD Therapeutics
Dr. Dean Tai, Singapore View Bio
Combined Q&A
UITC & ECHOSENS Lunch Symposium
Asia Perspective on Fatty Liver Disease
Dr. George Goh,  Singapore View Bio
Optimizing VCTETM assessment of MASLD
Prof. Vincent Wong, Hong Kong View Bio
Q&A Session
FibroScan® 630 Expert SSM Demo Session
Chairs: Dr. Edhel Tripon & Dr. Anand Kulkarni
Debate: Will incretin-based obesity treatment solve the MASLD epidemic?
Yes: Dr. Jiangao Fan, China View Bio
No: Prof. Vincent Wong, Hong Kong View Bio
An oasis in the desert: Understanding the THRß _pathway and its agonism in MASLD
Prof. Paul M. Yen, Singapore View Bio
Future of FGF21 in treatment of MASLD
Prof. Arun Sanyal, USA View Bio
Future of PPAR in treatment of MASLD
Prof. Sven Francque, Belgium View Bio
Can data for bariatric surgery be extrapolated to endobariatrics for MASLD?
Dr. George Goh,  Singapore View Bio
Combined Q&A
Tea Break
Chairs: Prof. Ajay Duseja & Prof. Phunchai Charatcharoenwitthaya
State of the art: Why are we not making progress with cirrhotic MASH patients?
Prof. Arun Sanyal, USA View Bio
Special considerations in managing the decompensated MASH cirrhotic patient
Dr. Mark Muthiah, Singapore View Bio,
Case based discussion

Moderators:

 

– Panel Speakers:

Combined Q&A
Closing: National health policy for MASLD
Prof. Dan Yock Young,Singapore View Bio
Advancing Care in MASLD Programme Time (SGT)
Welcome Address
Prof. Arun SanyalView Bio, Dr. Mark MuthiahView Bio
Is MASLD in lean patients the same disease as in overweight and obese individuals? A clinical viewpoint
Prof. Vincent WongView Bio
Is MASLD in lean patients the same disease as in overweight and obese individuals? A pathobiological viewpoint
Prof. Sven Francque View Bio
Similarities and differences between MetALD and MASLD
Prof. Ajay Duseja View Bio
Specific aetiology SLD in the Asian context
Dr. Daniel Huang QingyaoView Bio
Combined Q&A
Tea Break
Interpreting NIT data: Lessons from NIMBLE and LITMUS
Prof. Arun SanyalView Bio
Intelligent use of NIT’s in clinical practice – moving forward and back from primary care
Prof. Chan Wah Kheong View Bio
A patient centric view of risk assessment: balancing competing risks
Dr. Mark MuthiahView Bio
Artificial Intelligence in Liver Histology: Driving Development of MASLD Therapeutics
Prof. Dean Tai
Combined Q&A
Lunch
Debate: Will incretin-based obesity treatment solve the MASLD epidemic?
Yes:  TBC
 Prof. Vincent WongView Bio
Future of FGF21 and THR in treatment of MASLD
TBC
Future of PPAR in treatment of MASLD
Prof. Sven FrancqueView Bio
Can data for bariatric surgery be extrapolated to endobariatrics for MASLD?
Prof. George Goh Boon Bee View Bio
Combined Q&A
Tea Break
State of the art: Why are we not making progress with cirrhotic MASH patients?
Prof. Arun SanyalView Bio
Special considerations in managing the decompensated MASH cirrhotic patient
TBC
Managing DM in the decompensated cirrhotic – what should the MASH provider know about emerging trends in diabetes care?
Case based discussion
Moderators: Dr. Mark MuthiahView Bio, Dr. Daniel Huang QingyaoView Bio
Combined Q&A
Closing: National health policy for MASLD
Programme Time (SGT)
Welcome remarks Prof. Dan Yock Young
Session 1
NASH as a multisystem disorder- review of the evidence
Prof. Arun Sanyal View Bio
Host determinants on metabolic health and NASH progression
Dr. Mark Muthiah View Bio
Environmental drivers of end organ disease in NAFLD
Prof. Chan Wah Kheong View Bio
Discussion
– Prof. Tai E Shyong / Prof. Chan Wah Kheong View Bio
Tea Break
Session 2
Redefining NASH as a disease of accelerated aging
Prof. Arun Sanyal View Bio
The clinical / mechanistic basis for the liver-heart connection in NASH
Prof. Shadab Siddiqui View Bio
Thyroid hormone and NASH
Dr. Brijesh Kumar Singh
Discussion
Dr. Mark Muthiah View Bio / Prof. Chan Wah Kheong  View Bio
Lunch
Session 3 – Controversies
Alcohol is a major confounder in assessment and management of NASH
– For the motion: Prof. Ajay Duseja  View Bio
– Against the motion: Prof. Chan Wah Kheong  View Bio
Discussion
Prof. Dan Yock Young View Bio / Prof. Khin Maung Win
Break
Session 4
How to develop and evaluate a NIT
Prof. Arun Sanyal View Bio
Innovations in histological assessment- what will be the role of histology in NASH
Prof. Arun Sanyal View Bio
Status of current NITs for risk stratification and disease monitoring for NAFLD and metabolic health
Prof. Vincent Wong View Bio
Discussion
Prof. Shadab Siddiqui View Bio / Dr. Mark Muthiah View Bio
Tea Break
Session 5
Preparing Asia for Precision Medicine for NASH in the context of metabolic health
Prof. Dan Yock Young View Bio
Current best practises in the NASH patient
Dr. Mark Muthiah View Bio
Transplanting the decompensated NASH cirrhotic patient
Prof. Shadab Sidiqqui View Bio
Discussion
Prof. Ajay Duseja View Bio / Prof. Khin Maung Win
Challenges and Opportunities in NASH- a state of the art
Prof. Arun Sanyal View Bio